Literature DB >> 29773590

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.

Jorge J Castillo1,2, Joshua N Gustine3, Kirsten Meid3, Toni E Dubeau3, Lian Xu3, Guang Yang3,2, Zachary R Hunter3, Ranjana Advani4, Lia Palomba5, Steven P Treon3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29773590      PMCID： PMC6165799          DOI： 10.3324/haematol.2018.191999

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Robert J Manning; Christina Tripsas; Christopher J Patterson; Patricia Sheehy; Steven P Treon
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

Review 2.  Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.

Authors:  Jorge J Castillo; M Lia Palomba; Ranjana Advani; Steven P Treon
Journal:  Ther Adv Hematol       Date:  2016-06-13

3.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

4.  Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.

Authors:  Joshua N Gustine; Kirsten Meid; Toni Dubeau; Patricia Severns; Zachary R Hunter; Yang Guang; Lian Xu; Steven P Treon; Jorge J Castillo
Journal:  Am J Hematol       Date:  2018-01-25       Impact factor: 10.047

5.  Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Authors:  Paul M Barr; Jennifer R Brown; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Stephen P Mulligan; Ulrich Jaeger; Richard R Furman; Florence Cymbalista; Marco Montillo; Claire Dearden; Tadeusz Robak; Carol Moreno; John M Pagel; Jan A Burger; Samuel Suzuki; Juthamas Sukbuntherng; George Cole; Danelle F James; John C Byrd
Journal:  Blood       Date:  2017-04-03       Impact factor: 22.113

6.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Authors:  Lian Xu; Zachary R Hunter; Guang Yang; Yangsheng Zhou; Yang Cao; Xia Liu; Enrica Morra; Alessandra Trojani; Antonino Greco; Luca Arcaini; Marzia Varettoni; Maria Varettoni; Jennifer R Brown; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi; Christopher J Patterson; Robert J Manning; Christina K Tripsas; Neal I Lindeman; Steven P Treon
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

Authors:  Roger G Owen; Robert A Kyle; Marvin J Stone; Andy C Rawstron; Veronique Leblond; Giampaolo Merlini; Ramon Garcia-Sanz; Enrique M Ocio; Enrica Morra; Pierre Morel; Kenneth C Anderson; Christopher J Patterson; Nikhil C Munshi; Alessandra Tedeschi; Douglas E Joshua; Efstathios Kastritis; Evangelos Terpos; Irene M Ghobrial; Xavier Leleu; Morie A Gertz; Stephen M Ansell; William G Morice; Eva Kimby; Steven P Treon
Journal:  Br J Haematol       Date:  2012-11-15       Impact factor: 6.998
  7 in total
  4 in total

1.  Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.

Authors:  Aristea-Maria Papanota; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Meletios A Dimopoulos; Maria Gavriatopoulou
Journal:  J Blood Med       Date:  2019-08-27

Review 2.  Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.

Authors:  Shashank Cingam; Surbhi Sidana
Journal:  Blood Lymphat Cancer       Date:  2022-08-18

Review 3.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.

Authors:  Aqu Alu; Hong Lei; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-10-01       Impact factor: 23.168

4.  Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.

Authors:  Joshua N Gustine; Shayna Sarosiek; Catherine A Flynn; Kirsten Meid; Carly Leventoff; Timothy White; Maria Luisa Guerrera; Lian Xu; Amanda Kofides; Nicholas Tsakmaklis; Manit Munshi; Maria Demos; Christopher J Patterson; Xia Liu; Guang Yang; Zachary R Hunter; Andrew R Branagan; Steven P Treon; Jorge J Castillo
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 11.047
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.